stockrowBicycle Therapeutics PLC Sponsored ADR
BCYCBicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024.
- Revenue
- +190.2%
- EPS
- +82.4%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow BCYC
Alert me
Bicycle Therapeutics PLC Sponsored ADR (BCYC) EV/Sales
As of 6 November 2026, Bicycle Therapeutics PLC Sponsored ADR (BCYC) trades at a EV/Sales of −2.3×. Over the past ten years it has ranged from −12.8× (April 2025) to 111× (November 2021); the current reading is higher than 26% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.6× | — |
| FY2024 | −1.3× | — |
| FY2023 | 10.8× | (73.28%) |
| FY2022 | 40.4× | (57.79%) |
| FY2021 | 95.7× | 345.70% |
| FY2020 | 21.5× | 2,027.01% |
| FY2019 | 1.0× | — |
| FY2018 | −4.6× | — |
| FY2017 | −4.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | −2.3× | — |
| Jun 2026 | −3.2× | — |
| Mar 2026 | −3.4× | — |
| Dec 2025 | −1.6× | — |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. compare | −26.9× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | −2.3× |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| IVVD Invivyd, Inc. compare | 0.3× |
| CGEN Compugen Ltd. compare | 0.8× |
| WHWK Whitehawk Therapeutics, Inc. compare | 2.5× |
| TRDA Entrada Therapeutics, Inc. compare | 3.6× |
| ACOG Alpha Cognition Inc. compare | 9.2× |
| MDWD MediWound Ltd. compare | 12.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)